JP2019528320A - 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 - Google Patents

特発性肺線維症による慢性咳の治療のためのクロモリン組成物 Download PDF

Info

Publication number
JP2019528320A
JP2019528320A JP2019531577A JP2019531577A JP2019528320A JP 2019528320 A JP2019528320 A JP 2019528320A JP 2019531577 A JP2019531577 A JP 2019531577A JP 2019531577 A JP2019531577 A JP 2019531577A JP 2019528320 A JP2019528320 A JP 2019528320A
Authority
JP
Japan
Prior art keywords
cromolyn sodium
subject
pharmaceutical composition
cromolyn
mosm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019531577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528320A5 (enExample
Inventor
ゲアハルト ウィリアム
ゲアハルト ウィリアム
チュチュンキュー アフメット
チュチュンキュー アフメット
ソーニ プラビン
ソーニ プラビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respivant Sciences GmbH
Original Assignee
Respivant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivant Sciences GmbH filed Critical Respivant Sciences GmbH
Publication of JP2019528320A publication Critical patent/JP2019528320A/ja
Publication of JP2019528320A5 publication Critical patent/JP2019528320A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019531577A 2016-08-31 2017-08-29 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 Ceased JP2019528320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381914P 2016-08-31 2016-08-31
US62/381,914 2016-08-31
US201662417898P 2016-11-04 2016-11-04
US62/417,898 2016-11-04
PCT/US2017/049205 WO2018044942A1 (en) 2016-08-31 2017-08-29 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis

Publications (2)

Publication Number Publication Date
JP2019528320A true JP2019528320A (ja) 2019-10-10
JP2019528320A5 JP2019528320A5 (enExample) 2020-10-01

Family

ID=61301476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531577A Ceased JP2019528320A (ja) 2016-08-31 2017-08-29 特発性肺線維症による慢性咳の治療のためのクロモリン組成物

Country Status (7)

Country Link
US (4) US10265267B2 (enExample)
EP (1) EP3506893A4 (enExample)
JP (1) JP2019528320A (enExample)
CN (1) CN110139646A (enExample)
AU (1) AU2017321495A1 (enExample)
CA (1) CA3035528A1 (enExample)
WO (1) WO2018044942A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100990A1 (ko) * 2023-11-10 2025-05-15 (주)넥셀 특발성 폐섬유증 예방 또는 치료용 건조 분말 흡입 제형 및 이의 제조방법

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
WO2018067341A1 (en) * 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
US11311505B2 (en) * 2017-02-24 2022-04-26 Cellular Sciences, Inc. Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
WO2019067866A1 (en) * 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
AU2019309913B2 (en) * 2018-07-23 2025-02-27 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
CN110833538A (zh) * 2018-08-17 2020-02-25 北京盈科瑞创新药物研究有限公司 一种吸入用色甘酸钠溶液制剂及其制备方法和应用
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
CN111388456A (zh) * 2019-01-03 2020-07-10 江苏康缘药业股份有限公司 一种色甘酸钠雾化吸入溶液及其制备方法
US10709353B1 (en) 2019-10-21 2020-07-14 Sonavi Labs, Inc. Detecting a respiratory abnormality using a convolution, and applications thereof
US10702239B1 (en) 2019-10-21 2020-07-07 Sonavi Labs, Inc. Predicting characteristics of a future respiratory event, and applications thereof
US12433506B2 (en) * 2019-10-21 2025-10-07 Sonavi Labs, Inc. Digital stethoscope for counting coughs, and applications thereof
US10709414B1 (en) 2019-10-21 2020-07-14 Sonavi Labs, Inc. Predicting a respiratory event based on trend information, and applications thereof
US10716534B1 (en) 2019-10-21 2020-07-21 Sonavi Labs, Inc. Base station for a digital stethoscope, and applications thereof
US10750976B1 (en) * 2019-10-21 2020-08-25 Sonavi Labs, Inc. Digital stethoscope for counting coughs, and applications thereof
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
WO2022126105A1 (en) * 2020-12-07 2022-06-16 Mannkind Corporation Method and composition for treating pulmonary fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513300B2 (en) * 2001-11-29 2013-08-20 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
WO2015120392A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
WO2015120389A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders

Family Cites Families (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3686320A (en) 1965-03-25 1972-08-22 Fisons Pharmaceuticals Ltd Bis-phenoxy compounds
US3777033A (en) 1965-03-25 1973-12-04 Fisons Pharmaceuticals Ltd Bis-chromonyl pharmaceutical composi-tion and methods
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3720690A (en) 1970-04-10 1973-03-13 Fisons Pharmaceuticals Ltd Pharmaceutically active bis-carboxychromone compounds
US3683320A (en) 1970-05-08 1972-08-08 Bunker Ramo Coaxial cable connectors
CA958714A (en) 1970-09-03 1974-12-03 Peter B. Johnson Bis-chromone derivatives
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US4152448A (en) 1972-02-15 1979-05-01 Fisons Limited Method and composition for the treatment of a condition of the gastro intestinal tract
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
GB1475503A (en) 1973-12-19 1977-06-01 Fisons Ltd Topical compositions
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4189571A (en) 1978-02-07 1980-02-19 Fisons Limited Esters of cromoglycates
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4268519A (en) 1979-06-05 1981-05-19 Fisons Limited Method of treating otitis media
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
DE3365744D1 (en) 1982-01-22 1986-10-09 Fisons Plc Liposome and sodium cromoglycate compositions, and methods for their preparation
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4683135A (en) 1983-07-27 1987-07-28 Yeda Research And Development Co., Ltd. DSCG binding protein and process for preparing same
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
US4634699A (en) 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
GB8332450D0 (en) 1983-12-06 1984-01-11 Fisons Plc Method of treatment
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2167300B (en) 1984-11-23 1988-11-23 Fisons Plc Formulations
JPH0662601B2 (ja) 1985-08-16 1994-08-17 京都薬品工業株式会社 クロモグリク酸誘導体および抗アレルギ−剤
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
EP0304802B1 (en) 1987-08-25 1993-03-31 Dr. Kübler GmbH Pharmaceutical composition and the use thereof
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0413583A3 (en) 1989-08-18 1991-07-17 Dey Laboratories; Inc. Clear, stable cromolyn formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
US5753208A (en) 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
DE122008000012I2 (de) 1990-12-05 2012-04-12 Gen Hospital Corp Vorrichtung zum Behandeln einen Lungengefassverengung und von Asthma.
DE59107894D1 (de) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
ATE121971T1 (de) 1991-11-07 1995-05-15 Ritzau Pari Werk Gmbh Paul Flüssigkeitszerstäubervorrichtung.
EP0540775B1 (de) 1991-11-07 1997-07-23 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
US5618842A (en) 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
GB9214390D0 (en) 1992-07-07 1992-08-19 Fisons Plc Formulations
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
GB9317752D0 (en) 1993-08-26 1993-10-13 Fisons Plc New pharmaceutical use
ES2120471T3 (es) 1993-12-17 1998-11-01 Pari Gmbh Spezialisten Fuer Effektive Inhalation Boquilla de pulverizacion.
US5508451A (en) 1994-07-07 1996-04-16 Hoechst Celanese Corporation Process for the preparation of dialkali metal cromoglycates
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5576346A (en) 1995-04-03 1996-11-19 Ascent Pharmaceuticals, Inc. Process for treating uremic pruritus
US5552436A (en) 1995-04-03 1996-09-03 Ascent Pharmaceuticals, Inc. Process for treating hemangioma
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
GB9513218D0 (en) 1995-06-29 1995-09-06 Fisons Plc Inhalation device and method
WO1997024142A1 (fr) 1995-12-27 1997-07-10 Showa Yakuhin Kako Co., Ltd. Composition aqueuse contenant de l'acide cromoglycique
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997038693A1 (en) 1996-04-18 1997-10-23 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1014979A4 (en) 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5952353A (en) 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
JP2003525842A (ja) 1997-09-29 2003-09-02 インヘール セラピューティック システムズ， インコーポレイテッド 計量吸入器における使用のための安定化調製物
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
DE59904648D1 (de) 1998-08-04 2003-04-24 Jago Res Ag Muttenz Medizinische aerosolformulierungen
DE69931930T2 (de) 1998-08-07 2006-10-05 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
JP2002532520A (ja) 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
CA2358463A1 (en) 1999-01-08 2000-07-13 Virginia Commonwealth University Polymeric delivery agents and delivery agent compounds
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
ATE274955T1 (de) 1999-05-03 2004-09-15 Battelle Memorial Institute Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2003507411A (ja) 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 噴霧乾燥大多孔性粒子製剤
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
IL161968A0 (en) 2001-11-14 2005-11-20 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6596284B1 (en) 2002-04-30 2003-07-22 Thomas E. Fleming Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers
WO2003105898A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
AU2003247641A1 (en) 2002-06-27 2004-01-19 Centocor, Inc. Cngh0005 polypeptides, antibodies, compositions, methods and uses
US20040120956A1 (en) 2002-06-27 2004-06-24 Song Xiao-Yu R. CNGH0004 polypeptides, antibodies, compositions, methods and uses
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US7582297B2 (en) 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
US7247711B2 (en) 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
CA2531482A1 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20050026880A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
CA2544924A1 (en) 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
US20060078558A1 (en) 2003-11-12 2006-04-13 Whitsett Jeffrey A Diagnosis, prognosis and treatment of pulmonary diseases
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20050191246A1 (en) 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
IL160936A0 (en) 2004-02-05 2004-08-31 Scott A Cordray Nasal spray and wash
WO2005091853A2 (en) 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
MXPA06013251A (es) 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones de aril-cetona para suministrar agentes activos.
WO2005115468A1 (ja) 2004-05-26 2005-12-08 Reverse Proteomics Research Institute Co., Ltd. 新規創薬ターゲットならびにこれに作用する医薬
US20060069124A1 (en) 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
EP1799260A4 (en) 2004-09-29 2011-09-28 Centocor Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
EP1858485B1 (en) 2005-03-16 2013-09-11 Honeywell International Inc. Medicament delivery formulations, devices and methods
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
AU2012238334A1 (en) 2005-06-30 2012-11-01 Abbvie Inc. IL-12/p40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
US7566743B2 (en) 2005-11-18 2009-07-28 Mark Glazman System and method for medical treatment
DK1962869T3 (da) 2005-12-21 2013-06-24 Solaeromed Inc Behandling af luftvejssygdomme
ES2807928T3 (es) 2005-12-29 2021-02-24 Janssen Biotech Inc Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
MX2008010222A (es) 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
WO2007103970A2 (en) 2006-03-07 2007-09-13 Endacea, Inc. Compositions and methods for treating respiratory disorders
US20080035141A1 (en) 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
LT3339445T (lt) 2006-09-08 2020-10-26 Abbvie Bahamas Ltd. Baltymai, suryšantys interleukiną 13
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
CA2676930C (en) 2007-02-08 2015-09-08 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
US8252807B2 (en) 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
US20080214491A1 (en) 2007-03-02 2008-09-04 Logsdon Craig D Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
WO2008130718A1 (en) 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
US8445435B2 (en) 2007-09-28 2013-05-21 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
CA2703050A1 (en) 2007-10-15 2009-04-23 Janssen Pharmaceutica Nv Anti-amyloid antibodies, compositions, methods and uses
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
BRPI0817398A2 (pt) 2007-11-06 2015-04-07 3M Innovative Properties Co "método para fabricação de um dispositivo, dispositivo para inalação e dispositivo ou componente"
AU2008341217B2 (en) 2007-12-20 2012-04-12 Astrazeneca Ab Dispenser and method for entraining powder in an airflow 537
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
US9095621B2 (en) 2008-04-25 2015-08-04 Nektar Therapeutics Oligome-bis-chromonyl compound conjugates
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
CN104829718A (zh) 2008-07-08 2015-08-12 艾伯维公司 前列腺素e2结合蛋白及其用途
US20100087455A1 (en) 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20110195924A1 (en) 2008-10-08 2011-08-11 Logsdon Craig D Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
WO2010057214A2 (en) 2008-11-17 2010-05-20 Wayne State University Nanoparticles and porous particles and methods of making the same
BRPI0922807A2 (pt) 2008-12-04 2015-12-22 Abbott Lab imonuglobulinas de domínio variável duplo e usos dos mesmos
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2010208136B2 (en) 2009-01-29 2015-03-05 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20110110349A (ko) 2009-01-29 2011-10-06 아보트 러보러터리즈 Ｉｌ-1 결합 단백질
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
US8470805B2 (en) 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
JP2012525155A (ja) 2009-05-01 2012-10-22 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびこの使用
PL2248517T3 (pl) 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2012004412A (es) 2009-10-15 2012-05-08 Abbott Lab Proteinas de union a il-1.
JP2013507928A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
CA2795734A1 (en) 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
AU2015200579A1 (en) 2010-04-07 2015-02-26 Abbvie Inc. TNF-alpha binding proteins
NZ628792A (en) 2010-05-14 2016-03-31 Abbvie Inc Il-1 binding proteins
AU2016222339B2 (en) 2010-05-14 2017-11-23 Abbvie Inc. IL-1 binding proteins
US8586044B2 (en) 2010-05-28 2013-11-19 Northwestern University Treatment of chronic pelvic pain syndrome
US9592220B2 (en) 2010-06-17 2017-03-14 Aradigm Corporation Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
ES2535979T3 (es) 2010-07-21 2015-05-19 Astrazeneca Ab Inhalador
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2816803A1 (en) 2010-11-02 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
JP5996553B2 (ja) 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
JP5634313B2 (ja) * 2011-03-29 2014-12-03 富士フイルム株式会社 レジストパターン形成方法およびそれを用いたパターン化基板の製造方法
GB201110058D0 (en) 2011-06-15 2011-07-27 3M Innovative Properties Co Medicinal inhalation devices, valves and components thereof
EA201490538A1 (ru) 2011-09-06 2014-08-29 Верона Фарма Плк Лечение кашля и его приступов
WO2013101972A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2015509704A (ja) 2011-12-30 2015-04-02 アッヴィ・インコーポレイテッド 受容体に対する二重可変ドメイン免疫グロブリン
WO2013170655A1 (en) 2012-01-18 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
GB2498746A (en) 2012-01-26 2013-07-31 Innovata Biomed Ltd Inhaler which locks when empty
EP2819645A2 (en) 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
US20150018396A1 (en) 2012-03-08 2015-01-15 President And Fellows Of Harvard College Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
BR112014024287A2 (pt) 2012-03-27 2018-05-08 Duke University composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos
WO2013169473A1 (en) 2012-05-09 2013-11-14 Virginia Commonwealth University Dry powder inhaler (dpi) designs for producing aerosols with high fine particle fractions
WO2013177594A2 (en) 2012-05-25 2013-11-28 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
US9427534B2 (en) 2012-07-05 2016-08-30 Clement Clarke International Ltd. Drug delivery inhaler devices
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
ES2701093T3 (es) 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
WO2014078258A1 (en) 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Process for making agglomerates using acoustic mixing technology
WO2014115098A1 (en) 2013-01-26 2014-07-31 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and inflammation
WO2014144299A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
CN110652495A (zh) 2013-05-23 2020-01-07 Az治疗公司 用于递送色甘酸的方法
EP3865134A1 (en) 2013-08-23 2021-08-18 Afferent Pharmaceuticals Inc. Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US9492408B2 (en) 2013-10-24 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Protection from chemical-induced acute lung injury
GB2522727B (en) 2013-11-26 2017-01-25 Purity Health Pharma Ltd Pulmonary delivery devices
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
US11485787B2 (en) 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
US20150273119A1 (en) 2014-03-26 2015-10-01 Snu R&Db Foundation Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating
US20150306107A1 (en) 2014-04-24 2015-10-29 Jansfat Biotechnology Co., Ltd. SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
WO2015161510A1 (en) 2014-04-25 2015-10-29 Jansfat Biotechnology Co., Ltd. Saa derivative compound restores enos and inhibits oxidative stress-induced diseases in hypoxia
US20150337315A1 (en) 2014-05-20 2015-11-26 Michael M. Grunstein Compositions and methods targeting signaling by the g protein beta-gamma subunit for the treatment of asthma
DE102014009164A1 (de) 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
PL3152330T3 (pl) 2014-06-05 2021-09-13 Transgenion-International Institute For Regenerative Translational Medicine Gmbh SPOSOBY DIAGNOZOWANIA PRZEWLEKŁEJ OBTURACYJNEJ CHOROBY PŁUC (POChP) Z ZASTOSOWANIEM NOWYCH BIOMARKERÓW MOLEKULARNYCH
JP6755240B2 (ja) 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
US10604806B2 (en) 2014-06-05 2020-03-31 Transgenion—International Institute for Regenerative Translational Medicine GmbH Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
WO2016011254A1 (en) 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof
KR101749414B1 (ko) 2014-09-30 2017-06-21 주식회사 엘지화학 (메트)아크릴레이트 화합물, 이로부터 유도된 반복단위를 포함하는 코폴리머 및 호모폴리머
US20170235918A1 (en) 2014-10-25 2017-08-17 Sumner Bluffs, Llc. Systems and methods for determining compliance and efficacy of a dosing regimen for a pharmaceutical agent
WO2017011729A1 (en) * 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US20190046444A1 (en) 2015-09-14 2019-02-14 Vgsk Techologies, Inc. A sterically stabilized carrier for subcutaneous, sublingual, and oral therapeutics, compositions and methods for treating a mammal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513300B2 (en) * 2001-11-29 2013-08-20 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
WO2015120392A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
WO2015120389A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100990A1 (ko) * 2023-11-10 2025-05-15 (주)넥셀 특발성 폐섬유증 예방 또는 치료용 건조 분말 흡입 제형 및 이의 제조방법

Also Published As

Publication number Publication date
WO2018044942A1 (en) 2018-03-08
US20180193259A1 (en) 2018-07-12
EP3506893A1 (en) 2019-07-10
US20190175503A1 (en) 2019-06-13
CN110139646A (zh) 2019-08-16
US20180193305A1 (en) 2018-07-12
EP3506893A4 (en) 2020-01-22
US10463613B2 (en) 2019-11-05
US10265267B2 (en) 2019-04-23
CA3035528A1 (en) 2018-03-08
AU2017321495A1 (en) 2019-03-21
US20200155452A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
US10463613B2 (en) Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10596146B2 (en) Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9968586B2 (en) Mast cell stabilizers treatment for systemic disorders
US10391078B2 (en) Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10583113B2 (en) Cromolyn compositions for treatment of pulmonary fibrosis
CN110505873A (zh) 鼻内肾上腺素制剂及治疗疾病的方法
CN120227329A (zh) 用于治疗肺动脉高压的药物制剂及其制备方法

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190712

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200824

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200824

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200910

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200928

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210224